Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19

British Journal of Clinical Pharmacology

Volumn 44, Issue 2, 1997, Pages 186-189

  Bertilsson, Leif ^a   Tybring, Gunnel ^a   Widén, Jolanta ^a   Chang, Ming ^a   Tomson, Torbjörn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carbamazepine; CYP2C19; CYP3A4; Induction; Omeprazole

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; HYDROXYOMEPRAZOLE; OMEPRAZOLE; OMEPRAZOLE SULFONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; HYDROXYLATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030792284     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00630.x     Document Type: Article

References (17)

1. Andersson T, Regårdh C-G, Dahl-Puustinen M-L, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415-416.
2. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25-31.
3. Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195-1202.
4. Andersson T, Miners JO, Veronese M, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
5. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
6. Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A. Autoinduction of carbamazepine metabolism in children studied with a stable isotope technique. Clin Pharmacol Ther 1980; 27: 83-88.
7. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide - An update. Clin Pharmacokinet 1986; 11: 177-198.
8. Brodie MJ, Dichter MA. Antiepileptic drugs. New Engl J Med 1996; 334: 168-175.
9. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a Therapeutic Drug Monitoring service. Ther Drug Monit 1994; 16: 368-374.
10. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984; 309: 347-356.
11. Chang M, Tybring G, Dahl M-L, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-518.
12. Tomson T, Svensson JO, Hilton-Brown P. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 1989; 11: 533-539.
13. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians - Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-363.
14. Yue Q-Y, Tomson T, Säwe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994; 4: 193-198.
15. Zhou HH, Anthony LB, Wood AJJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30: 471-475.
16. Baciewicz AM, Self TH. Rifampicin drug interactions. Arch Int Med 1984; 144: 1667-1671.
17. Böttiger Y, Bertilsson L: No effect on plasma carbamazepine concentration with concomitant omeprazole treatment. Clin Drug Invest 1995; 9: 180-181.